Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)

被引：0
|
作者：
James Amamoo [1 ]
Riddhi Doshi [2 ]
Joshua Noone [1 ]
Lin Xie [1 ]
Cory Gamble [1 ]
Mico Guevarra [1 ]
Victoria Divino [2 ]
Justin Chen [2 ]
Aaron King [3 ]
机构：
[1] Novo Nordisk Inc.,
[2] IQVIA,undefined
[3] MedFirst Primary Care – Quarry,undefined
来源：
Diabetes Therapy | 2025年 / 16卷 / 5期
关键词：
BMI; GLP-1 receptor agonist; HbA1c; Healthcare resource utilization; Real-world evidence; Semaglutide; SGLT2i; Type 2 diabetes; Weight;
D O I：
10.1007/s13300-025-01721-y
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1033 / 1048
页数：15
相关论文
共 50 条
  • [21] Sodium-glucose co-transporter 2 inhibitors in acute heart failure: real-world prescription trends and outcomes analysis
    Mizobuchi, Saki
    Saito, Yuki
    Kitano, Daisuke
    Toyama, Kazuto
    Miyagawa, Masatsugu
    Koyama, Yutaka
    Fujito, Hidesato
    Kojima, Keisuke
    Murata, Nobuhiro
    Fukamachi, Daisuke
    Okumura, Yasuo
    ESC HEART FAILURE, 2024, 11 (01): : 410 - 421
  • [22] Could cardiorenal benefits of sodium-glucose co-transporter 2 inhibitors be extended to type 1 diabetes mellitus?
    Popovic, Djordje S.
    Stoian, Anca Pantea
    Papanas, Nikolaos
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2022, 36 (11)
  • [23] Analysis on reasons for discontinuations of sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus in real-world practices in Taiwan
    Lin, Yi-Han
    Shao, Shih-Chieh
    Chan, Yuk-Ying
    Chen, Hui-Yu
    Yang, Yea-Huei Kao
    Lai, Edward Chia-Cheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 43 - 43
  • [24] Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
    Chioma Uzoigwe
    Yuanjie Liang
    Sarah Whitmire
    Yurek Paprocki
    Diabetes Therapy, 2021, 12 : 1475 - 1489
  • [25] Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes
    Lam, Karen S. L.
    Chow, Chun Chung
    Tan, Kathryn C. B.
    Ma, Ronald C. W.
    Kong, Alice P. S.
    Tong, Peter C. Y.
    Tsang, Man Wo
    Chan, Tak Mao
    Tang, Sydney C. W.
    Lee, Ka Kui
    So, Wing Yee
    Tomlinson, Brian
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (06) : 1097 - 1108
  • [26] Sodium-glucose cotransporter 2 inhibitors reduce HbA1c and weight but increase infections
    Jaiswal, Gayatri
    Gandhi, Gunjan Y.
    ANNALS OF INTERNAL MEDICINE, 2014, 160 (02)
  • [27] Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
    Dandona, Paresh
    Chaudhuri, Ajay
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (05)
  • [28] Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
    Jeon, Ja Young
    Kim, Dae Jung
    DIABETES & METABOLISM JOURNAL, 2024, 48 (05) : 837 - 846
  • [29] Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study
    Wolffenbuttel, Bruce H. R.
    Brugts, Michel P.
    Catarig, Andrei-Mircea
    Clark, Alice
    Kok, Maarten
    Lieverse, Aloysius G.
    van Soest, Jaap
    ADVANCES IN THERAPY, 2023, 40 (03) : 920 - 933
  • [30] Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study
    Bruce H. R. Wolffenbuttel
    Michel P. Brugts
    Andrei-Mircea Catarig
    Alice Clark
    Maarten Kok
    Aloysius G. Lieverse
    Jaap van Soest
    Advances in Therapy, 2023, 40 : 920 - 933
12345